Xcout IntelImmunic, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Immunic, Inc. among biotech companies — ranked by similarity to what Immunic, Inc. actually does, not by market-cap band.
Subscribe to see Immunic, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Immunic, Inc. at a glance
Immunic, Inc. is a biotech company headquartered in New York City, United States, founded in 2016. It is publicly listed (IMUX) with a market capitalisation of $104.1M. Xcout tracks 43 named people at Immunic, Inc., including Erik Lundgren (Chief Executive Officer & Director).
Immunic, Inc. leadership
- Erik LundgrenChief Executive Officer & Director
- Daniel VittChief Executive Officer
- Jason TardioChief Operating Officer & President
- Glenn WhaleyChief Financial Officer
- Michael A. PanzaraChief Medical Officer
- Chitrang DavéChief Data & Digital Officer
37 more named people on record for Immunic, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Immunic, Inc. competitors
Ranked by semantic similarity — how close each company is to Immunic, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Immunic Therapeutics is a clinical-stage biopharmaceutical company developing orally administered small-molecule therapies for chronic inflammatory and autoimmune diseases. Its pipeline has focused particularly on multiple sclerosis, including the investigational drug vidofludimus calcium (IMU-838).
Biotechnology
Evommune is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, developing new treatments for immune-mediated chronic inflammatory diseases.
Biotechnology
Avere Therapeutics is a biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing oral therapies for the treatment of IL-23-driven inflammatory diseases.
Biotechnology
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is driven by its mission to develop oral small molecule therapies to treat inflammatory and immunologic diseases.
Similar biotech company
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Biotechnology
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Biotechnology
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Similar biotech company
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Similar biotech company
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Biotechnology
Immunis, Inc. is a private, clinical-stage biotechnology company founded in 2019 and headquartered in Irvine, California, pursuing novel secretome-based therapeutics for age-related diseases.
Similar biotech company
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Biotechnology
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Immunic, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Immunic, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →